title: ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma.
abstract: ImmunoCyt/uCyt is a fluorescent test combining three monoclonal antibodies. In this study, it has been tested as a complement to cytology in the detection of urothelial carcinoma in urine. It has been performed simultaneously with standard cytology and cystoscopy on 870 urine analyses from one hospital. In 136 cases, one or more bladder tumors were found. Overall sensitivity of cytology, ImmunoCyt/uCyt and combined analyses reached 29, 74 and 84%, respectively, and overall specificity was 98, 62 and 61%. The negative predictive value of cytology, ImmunoCyt/uCyt and both analyses was 88, 93 and 95%, respectively, and the positive predictive value was 70, 26 and 29%. The sensitivity of cytology for low malignant potential neoplasms, low- and high-grade papillary carcinomas was 6, 18 and 53%, while it reached 71, 79 and 93% when combined with ImmunoCyt/uCyt. The sensitivity of cytology for stages Ta, T1, T2 and over and Tis tumors was 12, 67, 47 and 50%, while it reached 78, 83, 79 and 100% when combined with ImmunoCyt/uCyt. In the absence of tumor on cystoscopy but with positive ImmunoCyt/uCyt, 18% of patients developed a tumor, 2-6 months later. Of the 109 cases diagnosed as suspicious for malignancy by cytology, a tumor was present in 30 cases and ImmunoCyt/uCyt was positive in 22 (73%) of them. In conclusion, ImmunoCyt/uCyt may be used to postpone cystoscopies in patients followed for bladder cancer and may help to save cytologist and pathologist screening time.
authors.affiliation: Department of Pathology, Centre Hospitalier Universitaire de Québec, L'Hôtel-Dieu de Québec, Laval University, Côte du Palais, Québec, Canada. bernard.tetu@chuq.qc.ca
authors.forename: Bernard
authors.initials: B
authors.lastname: Têtu
authors.forename: Rabi
authors.initials: R
authors.lastname: Tiguert
authors.forename: François
authors.initials: F
authors.lastname: Harel
authors.forename: Yves
authors.initials: Y
authors.lastname: Fradet
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000032:analysis / Q000276:immunology; D014408:Biomarkers, Tumor / Q000276:immunology / Q000652:urine*; D002272:Carcinoembryonic Antigen / Q000276:immunology / Q000652:urine; D003558:Cystoscopy; D003581:Cytodiagnosis / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D009077:Mucins / Q000276:immunology / Q000652:urine; D009367:Neoplasm Staging; D012680:Sensitivity and Specificity; D014571:Urologic Neoplasms / Q000175:diagnosis* / Q000652:urine; D019459:Urothelium / Q000737:chemistry / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D009077:Mucins